Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Condition:   Thymic Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Sunitinib Malate
Sponsors:   Dwight Owen;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 13, 2018 / by / in
Comments